Lo Zumandimine 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

If patients are reporting difficulty filling their Lo Zumandimine 28 Day prescriptions, this clinical briefing provides the background, prescribing alternatives, and patient access strategies you need. While Lo Zumandimine (Aurobindo Pharma) is not currently on the FDA Drug Shortage Database, pharmacy-level availability issues continue to affect patient access across the drospirenone/ethinyl estradiol drug class.

Current Availability Status (2026)

Lo Zumandimine 28 Day is not listed on the FDA Drug Shortage Database as of early 2026. The Aurobindo Pharma product (NDC 59651-029) remains an active, marketed product. However, the broader drospirenone/EE market has seen disruptions:

• Vestura (Teva) was fully discontinued as a brand.
• Certain Barr Laboratories drospirenone/EE NDCs were discontinued in mid-2025, reducing the number of active manufacturers in the market.
• Pharmacy-level stock gaps are driven by distributor allocation practices and brand fragmentation across the remaining active generics (Lo Zumandimine, Loryna, Nikki, Gianvi, Syeda).

AB-Rated Therapeutic Equivalents for Lo Zumandimine 28 Day

The following products are AB-rated equivalents containing drospirenone 3 mg / ethinyl estradiol 0.02 mg in the 24/4 regimen — therapeutically equivalent to Lo Zumandimine and approved for all three of its indications (contraception, PMDD, moderate acne):

• Loryna (drospirenone/EE) — Widely stocked; considered a reliable supply option at most major chains.
• Nikki (drospirenone/EE) — AB-rated; inactive ingredients are considered most similar to branded Yaz.
• Gianvi (drospirenone/EE) — AB-rated; manufactured by Teva Pharmaceuticals; widely available.
• Syeda (drospirenone/EE) — AB-rated equivalent; available at most national chains.
• Jasmiel (drospirenone/EE) — Less common but AB-rated and therapeutically equivalent.

Important Note: Zumandimine vs. Lo Zumandimine — These Are NOT Equivalent

Prescribers should be aware that Zumandimine (also Aurobindo) is a Yasmin generic — not a Yaz generic — and contains a higher estrogen dose:

• Lo Zumandimine: DRSP 3 mg / EE 0.02 mg; 24/4 regimen; FDA-approved for contraception, PMDD, and acne.
• Zumandimine: DRSP 3 mg / EE 0.03 mg; 21/7 regimen; FDA-approved for contraception only (not PMDD or acne).

Pharmacists cannot automatically substitute Zumandimine for Lo Zumandimine — they require different prescriptions. If a patient needs the PMDD or acne indication, ensure the prescription specifies 0.02 mg EE (the Yaz formulation) to avoid dispensing errors.

Prescribing Strategies to Maximize Patient Access

The following prescribing adjustments can significantly improve a patient's ability to fill their prescription:

1. Write by generic name with explicit substitution permission. Write 'drospirenone 3 mg / ethinyl estradiol 0.02 mg tablets — generic substitution permitted' instead of a specific brand. This allows pharmacists to dispense whichever equivalent is in stock.
2. Prescribe a 90-day supply. A 90-day (84-tablet) supply reduces the frequency of pharmacy visits from 12 to 4 per year, minimizing the chances of encountering stock issues.
3. List acceptable alternatives on the prescription. Include 'or Loryna, Nikki, Gianvi as acceptable substitutes' in the prescription notes. This gives pharmacists explicit permission without requiring a callback.
4. Direct patients to mail-order or telehealth options for ongoing management. Mail-order pharmacies often have more reliable generic inventory than retail chains.

Potassium Monitoring Considerations for Patients on DRSP

Drospirenone has antimineralocorticoid activity (spironolactone analogue) and can elevate serum potassium. For patients concomitantly taking ACE inhibitors, ARBs, NSAIDs, potassium-sparing diuretics, or potassium supplementation, consider checking serum potassium during the first treatment cycle. The FDA recommends this monitoring for patients with conditions predisposing to hyperkalemia.

Patient Access Tools for Your Practice

Consider directing patients to medfinder for providers. medfinder calls pharmacies in the patient's area to identify which ones have the prescribed medication in stock, then texts the results to the patient. This eliminates the need for patients to call multiple pharmacies themselves — a common source of delays and frustration during supply disruptions.

For a step-by-step provider guide to helping patients find Lo Zumandimine, see: How to Help Your Patients Find Lo Zumandimine In Stock: A Provider's Guide.